89 biotech investors in Europe
We list 89 biotech investors in Europe as of November 2026: 1 has an SEC filing on file and 88 were checked on the firm's own website or an official register, and the list was last checked on 9 Nov 2026. The cities with the most head offices on this list are Paris (11), Stockholm (5) and Barcelona (4).
Top 10 biotech investors in Europe, ranked by recent fund activity
Among firms with a published profile and a dated fund or deal in the last 24 months. The rule: Activity score out of 100: recency of the latest fund filing or dated deal (40: within 3 months 40, 6 months 30, 12 months 20, 24 months 10), share of the observed portfolio in this sector (30; 15 when the sector is stated only), size of the fund on file on a log scale (20) and completeness of the public record (10). It is a measure of activity and fit, not of quality or returns. The same rule orders the whole list; it is repeated in the method box.
M Ventures
Type: Corporate VC · HQ: Amsterdam, Netherlands · Focus: Biotech, Healthtech, AI, Deep Tech · Latest activity: Portfolio news, Oct 2026 · Private fund assets: $27M (SEC Form ADV)
Portfolio news dated Oct 2026; $27M on file (SEC Form ADV); 92% of its observed portfolio is biotech and life sciences; 8 named decision-makers on file.
HBM Partners
Type: Fund manager · HQ: Zug, Switzerland · Stages: Series A, Series B, Growth, Late stage · Focus: Biotech, Healthtech, Medtech · Latest activity: Portfolio news, Oct 2026 · Fund size or assets: $2.8B (own site)
Portfolio news dated Oct 2026; $2.8B on file (own site); states biotech and life sciences as a focus; 1 named decision-maker on file.
Andera Partners
Type: Fund manager · HQ: Paris, France · Stages: Seed, Series A, Series B, Growth · Focus: Biotech, Medtech, Healthtech, Generalist · Latest activity: Portfolio news, Sep 2026 · Fund size or assets: €6.0B (own site)
Portfolio news dated Sep 2026; €6.0B on file (own site); states biotech and life sciences as a focus.
Truffle Capital
Type: VC firm · HQ: Paris, France · Focus: Biotech, Healthtech, Medtech, Fintech · Latest activity: Portfolio news, Oct 2026 · Fund size or assets: €500M (own site)
Portfolio news dated Oct 2026; €500M on file (own site); states biotech and life sciences as a focus; 3 named decision-makers on file.
Fountain Healthcare Partners
Type: VC firm · HQ: Dublin, Ireland · Stages: Seed · Focus: Biotech, Healthtech, Medtech · Latest activity: Portfolio news, Oct 2026 · Fund size or assets: €425M (own site)
Portfolio news dated Oct 2026; €425M on file (own site); states biotech and life sciences as a focus; 2 named decision-makers on file.
NLC Health Ventures
Type: VC firm · HQ: Amsterdam, Netherlands · Stages: Pre-seed, Seed · Focus: Biotech, Healthtech, Medtech · Latest activity: New fund, Sep 2026 · Fund size or assets: €300M (own site)
Latest fund filing dated Sep 2026; €300M on file (own site); states biotech and life sciences as a focus; 4 named decision-makers on file.
Claris Ventures
Type: VC firm · HQ: Turin, Italy · Stages: Pre-seed, Seed, Series A · Focus: Biotech, Healthtech · Latest activity: New fund, Oct 2026 · Fund size or assets: €190M (own site)
Latest fund filing dated Oct 2026; €190M on file (own site); states biotech and life sciences as a focus; 4 named decision-makers on file.
Sofinnova Partners
Type: VC firm · HQ: France (London office) · Stages: Seed, Series A, Series B, Growth · Focus: Biotech, Healthtech, Fintech, Agritech · Latest activity: New fund, Nov 2025 · Fund size or assets: €4.0B (own site)
Latest fund filing dated Nov 2025; €4.0B on file (own site); 88% of its observed portfolio is biotech and life sciences; 8 named decision-makers on file.
Hadean Ventures
Type: VC firm · HQ: Norway · Stages: Seed, Series A, Series B · Focus: Biotech, Healthtech, Medtech · Latest activity: New deal, Sep 2026 · Fund size or assets: €230M (own site)
Dated new deal in Sep 2026; €230M on file (own site); states biotech and life sciences as a focus; 3 named decision-makers on file.
Angelor
Type: VC firm · HQ: Lyon, France · Stages: Seed, Series A · Focus: Biotech, Healthtech, Medtech, Food and Beverage · Latest activity: New deal, Sep 2026 · Fund size or assets: €100M (own site)
Dated new deal in Sep 2026; €100M on file (own site); states biotech and life sciences as a focus; 1 named decision-maker on file.
First 25 of 89 biotech investors in Europe
| Investor | Type | HQ | Stagesour research | Focusour research | Latest fund or deal | Fund sizeas filed or stated | Checked | Contacts |
|---|---|---|---|---|---|---|---|---|
| M Ventures | Corporate VC | Amsterdam, Netherlands | Biotech, Healthtech, AI, Deep Tech | Portfolio news, Oct 2026 | $27M (SEC Form ADV) | 4 Nov 2026 | 8 names, firm email · Unlock | |
| HBM Partners | Fund manager | Zug, Switzerland | Series A, Series B, Growth, Late stage | Biotech, Healthtech, Medtech | Portfolio news, Oct 2026 | $2.8B (own site) | 7 Nov 2026 | 1 name, firm email · Unlock |
| Andera Partners | Fund manager | Paris, France | Seed, Series A, Series B, Growth | Biotech, Medtech, Healthtech, Generalist | Portfolio news, Sep 2026 | €6.0B (own site) | 7 Nov 2026 | No contact on file |
| Truffle Capital | VC firm | Paris, France | Biotech, Healthtech, Medtech, Fintech | Portfolio news, Oct 2026 | €500M (own site) | 7 Nov 2026 | 3 names, firm email · Unlock | |
| Fountain Healthcare Partners | VC firm | Dublin, Ireland | Seed | Biotech, Healthtech, Medtech | Portfolio news, Oct 2026 | €425M (own site) | 7 Nov 2026 | 2 names, firm email · Unlock |
| NLC Health Ventures | VC firm | Amsterdam, Netherlands | Pre-seed, Seed | Biotech, Healthtech, Medtech | New fund, Sep 2026 | €300M (own site) | 7 Nov 2026 | 4 names, firm email · Unlock |
| Claris Ventures | VC firm | Turin, Italy | Pre-seed, Seed, Series A | Biotech, Healthtech | New fund, Oct 2026 | €190M (own site) | 7 Nov 2026 | 4 names, firm email · Unlock |
| Sofinnova Partners | VC firm | France (London office) | Seed, Series A, Series B, Growth | Biotech, Healthtech, Fintech, Agritech | New fund, Nov 2025 | €4.0B (own site) | 5 Nov 2026 | 8 names · Unlock |
| Hadean Ventures | VC firm | Norway | Seed, Series A, Series B | Biotech, Healthtech, Medtech | New deal, Sep 2026 | €230M (own site) | 7 Nov 2026 | 3 names, firm email · Unlock |
| Angelor | VC firm | Lyon, France | Seed, Series A | Biotech, Healthtech, Medtech, Food and Beverage | New deal, Sep 2026 | €100M (own site) | 7 Nov 2026 | 1 name · Unlock |
| 819 Capital Partners | VC firm | Deventer, Netherlands | Seed, Series A, Growth | Biotech, Healthtech, Medtech, Generalist | Portfolio news, Sep 2026 | €100M (own site) | 7 Nov 2026 | 1 name, firm email · Unlock |
| XISTA Science Ventures | VC firm | Klosterneuburg, Austria | Pre-seed, Seed | Biotech, Deep Tech, AI, Industrial Tech | Portfolio news, Oct 2026 | €96M (own site) | 7 Nov 2026 | 4 names, firm email · Unlock |
| Biovance Capital | VC firm | Lisbon, Portugal | Seed, Series A | Biotech, Healthtech | New deal, Sep 2026 | €60M (own site) | 7 Nov 2026 | 4 names · Unlock |
| Wellington Partners | VC firm | Munich, Germany | Series A, Series B, Growth | Biotech, Healthtech, Medtech | Portfolio news, May 2026 | €210M (own site) | 4 Nov 2026 | 8 names · Unlock |
| CRB Health Tech | VC firm | Madrid, Spain | Seed, Series A | Biotech, Healthtech, Medtech | New fund, Oct 2026 | 7 Nov 2026 | 5 names, firm email · Unlock | |
| Industrifonden | VC firm | Stockholm, Sweden | Seed, Series A, Series B, Growth | Biotech, Healthtech, Deep Tech, Climate Tech | Portfolio news, Oct 2026 | 7 Nov 2026 | 3 names, firm email · Unlock | |
| TVM Capital Life Science | VC firm | Munich, Germany | Seed, Series A, Series B, Growth | Biotech, Healthtech, Medtech | Portfolio news, Sep 2026 | 7 Nov 2026 | 4 names, firm email · Unlock | |
| BioGeneration Ventures | VC firm | Naarden, Netherlands | Seed, Series A | Biotech, Healthtech | Portfolio news, Sep 2026 | 7 Nov 2026 | 5 names, firm email · Unlock | |
| Gimv | Fund manager | Antwerp, Belgium | Growth, Late stage | Biotech, Healthtech, Consumer, Industrial Tech | Portfolio news, Sep 2026 | 7 Nov 2026 | firm email · Unlock | |
| Gilde Healthcare | Fund manager | Utrecht, Netherlands | Series A, Series B, Growth | Biotech, Healthtech, Medtech, Climate Tech | New fund, Feb 2026 | €3.0B (own site) | 7 Nov 2026 | firm email · Unlock |
| Seventure Partners | VC firm | Paris, France | Biotech, Healthtech, Food and Beverage, Generalist | Portfolio news, Nov 2026 | 7 Nov 2026 | 2 names, firm email · Unlock | ||
| XGEN Venture | VC firm | Milan, Italy | Seed, Series A | Biotech, Healthtech, Medtech | Portfolio news, Oct 2026 | 7 Nov 2026 | 3 names · Unlock | |
| SHS Capital | Fund manager | Tübingen, Germany | Growth | Biotech, Healthtech, Medtech | New fund, Feb 2026 | €270M (own site) | 7 Nov 2026 | 5 names, firm email · Unlock |
| Pureos Bioventures | VC firm | Switzerland | Biotech, Healthtech | Portfolio news, Oct 2026 | 7 Nov 2026 | 4 names · Unlock | ||
| Mérieux Equity Partners | Fund manager | Lyon, France | Seed, Series A, Series B | Biotech, Healthtech, Medtech | Investment listed in 2026 | €150M (own site) | 7 Nov 2026 | 5 names, firm email · Unlock |
You are seeing 25 of 89. The full list adds 64 more investors and 306 named decision-makers.
One-time payment. No subscription. No account.
Or get the free sample.
How these 89 break down
By European country
| European country | On this list | Share |
|---|---|---|
| France | 18 | 20% |
| Netherlands | 11 | 12% |
| Germany | 11 | 12% |
| Spain | 11 | 12% |
| Sweden | 7 | 8% |
| Austria | 4 | 4% |
| Belgium | 4 | 4% |
| Luxembourg | 4 | 4% |
By stage
| Stage | On this list | Share |
|---|---|---|
| Pre-Seed | 26 | 29% |
| Seed | 65 | 73% |
| Series A | 55 | 62% |
| Series B | 24 | 27% |
| Growth | 31 | 35% |
Stage is our research. A firm can back more than one stage.
By type
| Type | On this list | Share |
|---|---|---|
| VC firm | 64 | 72% |
| Fund manager | 11 | 12% |
| Government or university fund | 8 | 9% |
| Corporate VC | 2 | 2% |
| Venture debt | 2 | 2% |
Method and limits
- Source
- 1 of the 89 rows carries an SEC filing (Form D or Form ADV). All 89 have a website we checked. Filing date and fund size are SEC data where a filing exists. Stage, sector and check size are our research.
- Inclusion rule
- Organizations that back startups. Individuals, buyout funds and firms we found to be inactive are left out. Sector: the firm states biotech and life sciences as a focus on its own site, or we observed it in the firm's portfolio.
- Order
- Firms with a published profile come first. Activity score out of 100: recency of the latest fund filing or dated deal (40: within 3 months 40, 6 months 30, 12 months 20, 24 months 10), share of the observed portfolio in this sector (30; 15 when the sector is stated only), size of the fund on file on a log scale (20) and completeness of the public record (10). It is a measure of activity and fit, not of quality or returns.
- Last refreshed
- November 2026. Rows on this list were checked between 4 Nov 2026 and 9 Nov 2026.
- Fill rates
- Of 89 rows: stage 79, sector 89, fund size 37, website 89. In the paid file: named decision-makers on 77 rows, firm email on 63, LinkedIn page on 70, check size on 30.
- Corrections
- Email [email protected] or use the update form. We act within 5 working days.
Questions
How many biotech investors in Europe are there?
We list 89 as of November 2026. 45 of the 89 have a fund filing or a dated deal in the last 12 months. The cities with the most are Paris (11), Stockholm (5) and Barcelona (4).
Which biotech investors in Europe raised a new fund in the last 12 months?
2 of the 89 have a fund filing dated in the last 12 months: Claris Ventures (Oct 2026) and Ysios Capital (Mar 2026). 45 of the 89 have a fund filing or a dated deal in that time.
What is the typical fund size of biotech investors in Europe?
None of the 89 discloses a fund size on an SEC Form D, so there is no median to give. 37 rows carry a size or assets figure from another public source, for example M Ventures at $27M (SEC Form ADV) and HBM Partners at $2.8B (own site).
Which stage do most biotech investors in Europe back?
Of the 79 with a stage on file, seed (65), Series A (55) and growth-stage (31). A firm can back more than one stage, and 10 rows have no stage on file yet.
Where does the data on biotech investors in Europe come from and how often is it updated?
1 of the 89 rows has an SEC filing on file (Form D or Form ADV) and 88 were checked on the firm's own website or an official register. Filing date and fund size come from the filing. Stage, sector and check size are our research. Rows on this list were last checked on 9 Nov 2026 at the latest. The whole file is re-verified twice a year.
Can I download the list of biotech investors in Europe as a spreadsheet?
Yes. The file holds all 89 rows in Excel and CSV, with 306 named decision-makers and 63 firm emails, for $49 one-time. 25 rows are free on this page.
Related lists
Consumer investors in Europe (65)Edtech investors in Europe (35)Proptech investors in Europe (37)Climate tech investors in Europe (250)Deep tech investors in Europe (299)Hardware investors in Europe (18)Impact investors in Europe (52)Food and beverage investors in Europe (67)Biotech venture capital firms in the US (297)Healthtech investors in Europe (291)SaaS investors in Europe (239)AI investors in Europe (230)Fintech investors in Europe (140)Energy investors in Europe (103)B2B investors in Europe (102)Biotech investors in the UK (92)Cybersecurity investors in Europe (64)Agritech investors in Europe (63)
Not sure this is the right list? Describe your raise in the investor matching tool and get a shortlist. The link opens it set to biotech and life sciences and Europe. Guide: how to build an investor list. Markdown version of this page.
Check the quality first
A free sample of 100 investors, every column, with sources and dates.